ARTL
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Artelo Biosciences files a new provisional patent application for ART27.13 in obesity, both alone and with GLP-1 receptor agonists, following unexpected nonclinical findingsSep 23, 2026
- Artelo Biosciences reported that ART27.13 produced weight loss comparable to semaglutide alone and doubled weight loss when combined with semaglutide in a nonclinical obesity modelSep 16, 2026
- Artelo Biosciences received a notice of allowance in Japan for patent claims covering the intended commercial formulation of ART27.13Aug 21, 2026
- Artelo announced enrollment of the first patient in a Phase 2 trial evaluating ART27.13 for glaucomaAug 11, 2026
- Artelo Biosciences reported positive nonclinical results for ART27.13 in paclitaxel-induced peripheral neuropathyJul 14, 2026